Martin Marietta Materials Inc
Change company Symbol lookup
Select an option...
MLM Martin Marietta Materials Inc
VMC Vulcan Materials Co
SHLDQ Sears Holdings Corp
COTRP Corts Trust for JC Penney Debentures
M Macy's Inc
DDS Dillard's Inc
KSS Kohls Corp
MC Moelis & Co
MSFT Microsoft Corp
FRPH FRP Holdings Inc
Go

Materials : Construction Materials | Mid Cap Blend
Company profile

Martin Marietta Materials, Inc. is a natural resource-based building materials company. The Company supplies aggregates (crushed stone, sand, and gravel) through its network of approximately 310 quarries, mines and distribution yards in Canada and The Bahamas. In the southwestern and western United States, the Company also provides cement and downstream products and services, including ready-mixed concrete, asphalt, and paving services, in markets that are naturally vertically integrated. The Company has cement plants in Texas, and ready mixed concrete and asphalt operations in Texas, Colorado, and Wyoming. Asphalt operations and paving services are in Colorado. The Company conducts its Building Materials Business through two segments, East Group and West Group. The East Group provides aggregates products only. The West Group provides aggregates, cement, and downstream products. The Company’s Magnesia Specialties Business includes magnesia-based chemicals and dolomitic lime businesses.

Postmarket

Last Trade
Delayed
$368.36
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$368.36
Day's Change
0.45 (0.12%)
Bid
--
Ask
--
B/A Size
--
Day's High
379.54
Day's Low
363.51
Volume
(Average)
Volume:
693,156

10-day average volume:
636,620
693,156

SHAREHOLDER ALERT: Robbins LLP Investigates Spectrum Pharmaceuticals, Inc. (SPPI) for Misleading Shareholders

6:02 am ET November 3, 2021 (BusinessWire) Print

Shareholder rights law firm Robbins LLP is investigating Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) to determine whether certain Spectrum officers and directors violated the Securities Exchange Act of 1934. Spectrum is a biopharmaceutical company that develops and commercializes oncology and hematology drug products. One product the Company has under development is ROLONTIS (eflapegrastim), a novel long-lasting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia.

If you would like more information about Spectrum Pharmaceuticals, Inc.'s misconduct, click here.

Spectrum Pharmaceuticals, Inc. (SPPI) Accused of Materially Misrepresenting the Likelihood ROLONTIS Would be Approved by the FDA

According to a class action complaint filed on behalf of Spectrum shareholders, Spectrum submitted a Biologics License Application ("BLA") to the U.S. Food and Drug Administration ("FDA") for ROLONTIS as a treatment chemotherapy-induced neutropenia (the "ROLONTIS BLA") in December 2018. In March 2019, Spectrum voluntarily withdrew its ROLONTIS BLA, and then resubmitted an updated ROLONTIS BLA in October 2019. During the relevant period, defendants touted the viability of ROLONTIS and the preparations the Company had made in advance of the FDA's inspection of its manufacturing facility. However, defendants made materially false and misleading statements and/or failed to disclose that the ROLONTIS manufacturing facility maintained deficient controls and/or procedures and that the deficiencies decreased the likelihood that the FDA would approve the ROLONTIS BLA in its current form. As a result, Spectrum had materially overstated the ROLONTIS BLA's approval prospects.

On August 6, 2021, Spectrum announced receipt of a Complete Response Letter ("CRL") from the FDA regarding the ROLONTIS BLA. The CRL cited deficiencies related to manufacturing and indicated that a reinspection of the Company's manufacturing facility would be necessary. On this news, Spectrum's stock price fell $0.70 per share, or over 21%, to close at $2.55 per share on August 6, 2021.

Spectrum Pharmaceuticals, Inc. (SPPI) shareholders have legal options. If you own shares of Spectrum Pharmaceuticals, Inc., contact us for more information about your rights.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas (800) 350-6003 adumas@robbinsllp.com Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Spectrum Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005420/en/

SOURCE: Robbins LLP

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com 
(800) 350-6003
www.robbinsllp.com
comtex tracking

COMTEX_396279341/1006/2021-11-03T06:02:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.